Ferric nitrilotriacetate

Cat. No.: HY-145157 Purity: 98.0%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Ferric nitrilotriacetate 화학구조

CAS No. : 16448-54-7

사이즈	재고	수량
무료 샘플 (0.1 - 0.2 mg)	지금 신청하기
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 Customer Validation

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
순도&문서
References
고객리뷰

제품 설명	Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis^[1].
In Vivo	Note: Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment. Ferric nitrilotriacetate can be used in animal modeling to create renal tumor and diabetes models. After intraperitoneal injection into mice, it deposits heavily in the liver and pancreas^[1]^[2]^[3]^[4]. Induction of renal tumors^[3] Background Ferric nitrilotriacetate can induce oxidative stress, leading to lipid peroxidation of renal cell membranes and DNA damage, thereby promoting the development of renal tumors^[1]^[2]. Specific Modeling Methods Mice: A/J • male • 4-week-old Administration: 1.8-2.7 mg of Fe/kg • ip • once daily, 6 days a week for 12 weeks Note 1.8 to 2.7 mg refers to the amount of Fe contained in ferric nitrilotriacetate. Modeling Indicators Pathological Changes: The renal proximal tubular (PCT) cells in mice exhibit degeneration, necrosis, and shedding. Many PCT cells show regenerative characteristics, with some regenerative cells being abnormally large and featuring prominent nucleoli and mitoses. Some regenerative cells lack tubular formation. Phenotypic Observations: Renal tubular cell tumors develop. The appearance of renal tumors includes solid, cystic, or hemorrhagic forms. Microscopic examination reveals tumor cells with clear, granular, or spindle shapes, forming solid aggregates, papillae, cysts, or glandular patterns. Correlated Product(s): / Opposite Product(s): / Induction of diabetes^[4] Background Ferric nitrilotriacetate causes significant iron deposition in the pancreas, leading to oxidative stress through the generation of reactive oxygen species (ROS) and free radicals. This results in damage and functional failure of pancreatic islet β-cells, reducing insulin secretion and consequently inducing diabetes.^[4]. Specific Modeling Methods Rat: Wistar • male and female Administration: 200 mg/rat • ip • once daily, Specifics of the administration method are detailed in the note Note Rats received intraperitoneal injections of Ferric nitrilotriacetate, with each rat receiving a total of approximately 200 mg of iron. The dosage and frequency of administration were as follows: Weeks 1-3: 2 mg Fe/kg, once daily; Weeks 3-6: 6 mg Fe/kg, once daily; Next 2 months: 10 mg Fe/kg, once daily. Modeling Indicators Pathological Changes: Significant iron deposition was observed in the exocrine cells of the pancreas in mice, with a reduction in insulin-storing β granules in the islet β cells and a decrease in zinc ion content. Phenotypic Observations: Mice exhibited diabetic symptoms, including hyperglycemia, glycosuria, ketonemia, and ketonuria. Correlated Product(s): / Opposite Product(s): / MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
분자량	243.96
화학식	C₆H₆FeNO₆
CAS No.	16448-54-7
Appearance	Solid
Color	Light yellow to yellow
SMILES	O=C1[O-][Fe+3]([O-]C2=O)([O-]3)[N](C2)(C1)CC3=O
선적	Room temperature in continental US; may vary elsewhere.
보관	4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
순도&문서	Purity: 98.0% Select Batch: Data Sheet (277 KB) SDS (252 KB) COA (246 KB) Handling Instructions (2659 KB)
References	[1]. Joël Essogo J, et al. Zanthoxylum heitzii Modulates Ferric Nitrilotriacetate-Dependent Oxidative Alterations in Four Vital Organs: An In Vitro Organoprotective Model. Evid Based Complement Alternat Med. 2017;2017:6058150. [Content Brief] [2]. Inoue S, et al. Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987 Dec 15;47(24 Pt 1):6522-7. [Content Brief] [3]. Li JL, et al. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 1987 Apr 1;47(7):1867-9. [Content Brief] [4]. Awai M, et al. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol. 1979 Jun;95(3):663-73. PMID: 377994; [Content Brief]